James Kearns, MD, discusses genetic correction of prostate-specific antigen (PSA) and how it can reduce the number of patients diagnosed with potentially insignificant prostate cancer
James Kearns, MD
Advertisement
Articles by James Kearns, MD
Advertisement
Latest Updated Articles
Dr. Kearns Discusses PSA Genetic Correction in Prostate CancerPublished: September 3rd 2015 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
